Press Release | April 2, 2024
Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer
Read More
News | March 25, 2024
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Read More
News | February 21, 2024
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases
Read More
Press Release | February 15, 2024
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
Read More